Acadian Asset Management
ANTX icon

Acadian Asset Management’s AN2 Therapeutics ANTX Stock Holding History

Acadian Asset Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-42,335
Closed -$45K – 1618
2024
Q3 		$45K Sell
42,335
-44,613
-51% -$77.4K ﹤0.01% 1821
2024
Q2 		$185K Sell
86,948
-76,548
-47% -$182K ﹤0.01% 1439
2024
Q1 		$529K Buy
+163,496
New +$1.78M ﹤0.01% 992

Other funds holding ANTX

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

Acadian Asset Management's ANTX Position: Q4 2024 in Review

Acadian Asset Management sold out of AN2 Therapeutics (ANTX) in Q4 2024, closing a stake of 42,335 shares — an estimated $45K sold.

Acadian Asset Management first reported a position in ANTX in Q1 2024 and held it in 3 quarters. The position peaked at $529K in Q1 2024. 37 funds tracked by Wall St. Rank hold ANTX as of Q4 2024.

  • Acadian Asset Management reported no remaining AN2 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 42,335 AN2 Therapeutics shares in Q4 2024, an estimated $45K.
  • Acadian Asset Management first reported a position in AN2 Therapeutics in Q1 2024 and held it in 3 quarters.
  • Acadian Asset Management's AN2 Therapeutics position peaked at $529K in Q1 2024.
  • 37 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.